The Child with Immune Thrombocytopenic Purpura: Is Pharmacotherapy or Watchful Waiting the Best Initial Management? A Panel Discussion from the 2002 Meeting of the American Society of Pediatric Hematology/Oncology

Paula Bolton-Maggs, Michael D. Tarantino, George R. Buchanan, James B. Bussel, James N. George

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

The initial management of immune thrombocytopenic purpura is a topic of debate among pediatric hematologists. The decision whether to start a patient on pharmacotherapy or to employ an approach of watchful waiting and patient education is problematic for this group of physicians. A wide variety of research studies and review articles have been published on either side of this debate. Here, the proceedings from a panel discussion, held at the 2002 American Society of Pediatric Hematology/Oncology meeting, are presented. The panel, composed of experts on both sides of the debate, presented the rationale, benefits, and risks of both pharmacotherapy and the watchful waiting strategy.

Original languageEnglish (US)
Pages (from-to)146-151
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume26
Issue number2
DOIs
StatePublished - Feb 1 2004

Keywords

  • Anti-D
  • Idiopathic (immune) thrombocytopenic purpura
  • Immune globulin
  • Intracranial hemorrhage
  • Platelets

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'The Child with Immune Thrombocytopenic Purpura: Is Pharmacotherapy or Watchful Waiting the Best Initial Management? A Panel Discussion from the 2002 Meeting of the American Society of Pediatric Hematology/Oncology'. Together they form a unique fingerprint.

  • Cite this